Article Sidebar

PDF (Tiếng Việt)
Published: 2021-06-21
Abstract Views: 246
Views PDF (Tiếng Việt): 170
DOI: https://doi.org/10.52163/yhc.v62i4%20(2021).107
Issue
Vol. 62 No. 4 (2021)
Section
Articles
How to Cite
Tri, B. D. M., Anh, L. C. D. ., Mai, D. V., Phuc, N. H., & Thuy Linh, N. T. (2021). EFFECTS OF TRASTUZUMAB ON MYOCARDIAL FUNCTION ON BREAST CANCER PATIENTS. Vietnam Journal of Community Medicine, 62(4 (2021). https://doi.org/10.52163/yhc.v62i4 (2021).107

EFFECTS OF TRASTUZUMAB ON MYOCARDIAL FUNCTION ON BREAST CANCER PATIENTS

Bui Dang Minh Tri1, Le Cong Duy Anh2, Do Van Mai2, Nguyen Huu Phuc2, Nguyen Thi Thuy Linh
1 University of Medicine Pham Ngoc Thach
2 Tay Do University

Main Article Content

Abstract

Objective: To investigate the effect of Trastuzumab on myocardial function on breast cancer patients at Thong Nhat hospital. Subjects and methods: a retrospective study on 48 patients with breast cancer treated with Trastuzumab at Thong Nhat hospital. Results: Percentage of patients with heart failure according to the Frammingham diagnostic criteria was 4.17%. The proportion of patients with no symptoms of heart failure according to Frammingham diagnostic criteria was 95.83%. According to the degree of EF change, the proportion of patients with decreased EF > 10% after treatment was 43.75%. With 9 patients with EF < 53%, accounting for 18.75%. The proportion of patients who had to discontinue therapy due to cardiotoxicity during treatment with Trastuzumab was 12.5%, with 6.25% stopping completely and 6.25% of patients stopping temporarily. Conclusion: the rate of patients with heart failure was little, the proportion of EF <53% was low. The proportion of patients who had to discontinue therapy due to cardiotoxicity during treatment with Trastuzumab was low.

Article Details

Keywords

Breast cancer, myocardial function, Trastuzumab

References

1. Balduzzi S, Mantarro S, Guarneri V et al. Trastuzumab-containing regimens for metastatic breast cancer, Cochrane Database Syst Rev, 2014; 6: CD006242.
2. Joanna H, Leś D, Sarzyczny SD et al. Cardiac side effects of trastuzumab in breast cancer patients - single centere experiences, Contemporary oncology, 2013; 17(2): 190–195.
3. Seidman A, Hudis C, Pierri MK et al., Cardiac dysfunction in the trastuzumab clinical trials experience, J Clin Oncol, 2002; 20(5): 1215-21.
4. Somaira N, Aziz K, Park JY et al., Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction, J Am Heart Assoc., 2018; 7(15): e008637.
5. Serrano C, Cortés J, De Mattos AL et al., Trastuzumab – related cardiotoxicity in the elderly: a role for cardiovascular risk factors, Ann Oncol., 2012; 23: 897-902.
6. Tan-Chiu E, Yothers G, Romond E et al., Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31, J Clin Oncol., 2005; 23(31) :7811-7820.